FRAT1 (FRAT regulator of Wnt signaling pathway 1) is a proto-oncogene that positively regulates the canonical Wnt/β-catenin signaling pathway by inhibiting GSK-3-mediated phosphorylation of β-catenin 1. Originally characterized in advanced T-cell lymphoma 1, FRAT1 is located on chromosome 10.1 2 and functions as a GSK-3β-binding protein that stabilizes β-catenin, promoting TCF-mediated transcription 2. FRAT1 overexpression is associated with multiple human malignancies. Elevated FRAT1 expression correlates significantly with pathologic grade, tumor proliferation, and poor prognosis across diverse cancer types including astrocytomas, glioblastomas, non-small cell lung cancer, and gastric cancer 134. In gastric cancer, FRAT1 and its homolog FRAT2 are co-upregulated and promote carcinogenesis through Wnt pathway activation 2. Mechanistically, FRAT1 knockdown suppresses cell proliferation, migration, invasion, and xenograft growth in glioblastoma models 5. Additionally, FRAT1 expression can be therapeutically modulated; luteolin reduces keloid fibroblast proliferation by downregulating FRAT1 6. FRAT1 serves as a potential biomarker for malignancy diagnosis, prognostic stratification, and emerging therapeutic target in multiple tumor types.